The CSL Limited (ASX: CSL) share price got knocked down around 4% today after the biopharmaceutical giant released its latest round of financial results to investors.
CSL is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition.
Today, CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
This morning, CSL delivered its half-year results for 2019. Rask Media’s Max Wagner went into depth covering the results in this article, “Everything You Should Know About CSL’s Report“.
In brief, CSL reported another half-year of profit growth, up 10% in constant currency terms, and revealed it would pay a dividend equivalent to $1.20 per share, up 20%.
CSL also set its full-year profit expectations at the upper end of its range between $1.88 billion and $1.95 billion. That’s promising!
Will The CSL Share Price Reach $200?
In a recent analysis of CSL shares, Rask Media’s Owen Raszkiewicz wrote an article asking, “Is The CSL Share Price Seriously Cheap?“.
While shares are down today, CSL has a knack for grinding its share price higher and higher again over many years so it could be one to watch closely — especially if it falls any further.
Here are 3 stocks I own in April 2020...
Amidst the COVID-19 confusion, there are some companies still growing FAST (think: online meetings through Zoom, streaming companies like Netflix and eHealth services provided by Teledoc).
While the world grapples with COVID-19, some companies are still growing rapidly. The entire cloud computing market is valued around $US210 billion but if you ask me, it seems clear as day that this market is only going to get bigger in 2020 and beyond.
That's why our top investment analyst has just identified 3 growth stocks in a net cash position, with strong competitive forces... and obvious tailwinds at their back. He owns all three of them right now!
Claim a FREE investing report on our analyst's "3 best share ideas for the cloud revolution" when you create a free Rask Australia account.
Our report is 100% free and unlocks hundreds of hours of bonus content.
Disclaimer and warning: The information on this website is general financial advice only. That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please read our Terms of Service and Financial Services Guide before using this website.